Press releases
Dec 1, 2020
Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM–002 (S-oxprenolol) for Treating Cancer Cachexia
READ MORE
Nov 23, 2020
Actimed Therapeutics Licenses Additional European Patent Rights to S-oxprenolol in ALS from Charité – Universitätsmedizin Berlin
READ MORE
Oct 22, 2020
Actimed Therapeutics to present at upcoming Bio-Europe conference as one of 'Scrip’s 10 to watch'
READ MORE
Sep 2, 2020
Actimed Therapeutics appoints Dr Chika Yoshinaga as Development, Partnering and Financing Advisor in Japan and China
READ MORE
Apr 2, 2020
Actimed Therapeutics appoints Annalisa Jenkins as Advisor
READ MORE
Oct 30, 2019
Actimed Therapeutics appoints Robin Bhattacherjee as CEO
READ MORE
Oct 31, 2018
Actimed Therapeutics, the Cachexia Company, Raises £1.25m in Seed A Round
READ MORE
Apr 5, 2018
Actimed Therapeutics appoints pharma veteran Dr David Ebsworth as Chairman
READ MORE